Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. Yang, A., Shi, J., Luo, Y., Ye, Y., Tan, Y., Huang, H., & Zhao, Y. Scientific Reports, 9(1):20402, December, 2019. doi abstract bibtex Patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of acquiring tuberculosis (TB) due to a status of immunosuppression. We conducted a nested case control study to investigate the incidence and risk factors for TB after allo-HSCT. Between 2012 and 2017, 730 consecutive allo-HSCT recipients were enrolled, and 14 patients (1.92%) were diagnosed with TB. Relatively, 54 allo-HSCT recipients were selected as control. Patients who suffered TB had a significantly higher 3-year non-relapse mortality rate than the control group (30.36% vs 5.39%, P \textless 0.01). In multivariate analysis, invasive fungal disease (HR 4.87, 95% CI 1.39-17.09), treatment with a relatively high dose of prednisone (HR 10.34, 95% CI 1.12-95.47) and treatment with tacrolimus (HR 4.79, 95% CI 1.18-19.44) were identified independent risk factors for TB occurrence post allo-HSCT (P \textless 0.05). Meanwhile, donor type, dose and type of anti-thymocyte globulin (ATG) administrated, as well as treatment intensity, did not alter the incidence of TB. Therefore, allo-HSCT recipients with unexplained fever, especially those who suffer from invasive fungal disease and ongoing immunosuppression with a relatively high dose of prednisone or tacrolimus, are at a high-risk of developing active TB. Closely Monitoring TB occurrence, making a timely diagnosis and administering the proper treatment may be beneficial to those high-risk patients.
@article{yang_allo-hsct_2019,
title = {Allo-{HSCT} recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis},
volume = {9},
issn = {2045-2322},
doi = {10.1038/s41598-019-56013-w},
abstract = {Patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of acquiring tuberculosis (TB) due to a status of immunosuppression. We conducted a nested case control study to investigate the incidence and risk factors for TB after allo-HSCT. Between 2012 and 2017, 730 consecutive allo-HSCT recipients were enrolled, and 14 patients (1.92\%) were diagnosed with TB. Relatively, 54 allo-HSCT recipients were selected as control. Patients who suffered TB had a significantly higher 3-year non-relapse mortality rate than the control group (30.36\% vs 5.39\%, P {\textless} 0.01). In multivariate analysis, invasive fungal disease (HR 4.87, 95\% CI 1.39-17.09), treatment with a relatively high dose of prednisone (HR 10.34, 95\% CI 1.12-95.47) and treatment with tacrolimus (HR 4.79, 95\% CI 1.18-19.44) were identified independent risk factors for TB occurrence post allo-HSCT (P {\textless} 0.05). Meanwhile, donor type, dose and type of anti-thymocyte globulin (ATG) administrated, as well as treatment intensity, did not alter the incidence of TB. Therefore, allo-HSCT recipients with unexplained fever, especially those who suffer from invasive fungal disease and ongoing immunosuppression with a relatively high dose of prednisone or tacrolimus, are at a high-risk of developing active TB. Closely Monitoring TB occurrence, making a timely diagnosis and administering the proper treatment may be beneficial to those high-risk patients.},
language = {eng},
number = {1},
journal = {Scientific Reports},
author = {Yang, Apeng and Shi, Jimin and Luo, Yi and Ye, Yishan and Tan, Yamin and Huang, He and Zhao, Yanmin},
month = dec,
year = {2019},
pmid = {31892702},
pmcid = {PMC6938515},
keywords = {Adolescent, Adult, Aged, Case-Control Studies, Child, Disease Susceptibility, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppression Therapy, Immunosuppressive Agents, Incidence, Invasive Fungal Infections, Male, Methotrexate, Middle Aged, Mycophenolic Acid, Prednisone, Risk, Transplant Recipients, Tuberculosis, Young Adult},
pages = {20402},
}
Downloads: 0
{"_id":"oCiFv5p2ExsqWzkxb","bibbaseid":"yang-shi-luo-ye-tan-huang-zhao-allohsctrecipientswithinvasivefungaldiseaseandongoingimmunosuppressionhaveahighriskfordevelopingtuberculosis-2019","author_short":["Yang, A.","Shi, J.","Luo, Y.","Ye, Y.","Tan, Y.","Huang, H.","Zhao, Y."],"bibdata":{"bibtype":"article","type":"article","title":"Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis","volume":"9","issn":"2045-2322","doi":"10.1038/s41598-019-56013-w","abstract":"Patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of acquiring tuberculosis (TB) due to a status of immunosuppression. We conducted a nested case control study to investigate the incidence and risk factors for TB after allo-HSCT. Between 2012 and 2017, 730 consecutive allo-HSCT recipients were enrolled, and 14 patients (1.92%) were diagnosed with TB. Relatively, 54 allo-HSCT recipients were selected as control. Patients who suffered TB had a significantly higher 3-year non-relapse mortality rate than the control group (30.36% vs 5.39%, P \\textless 0.01). In multivariate analysis, invasive fungal disease (HR 4.87, 95% CI 1.39-17.09), treatment with a relatively high dose of prednisone (HR 10.34, 95% CI 1.12-95.47) and treatment with tacrolimus (HR 4.79, 95% CI 1.18-19.44) were identified independent risk factors for TB occurrence post allo-HSCT (P \\textless 0.05). Meanwhile, donor type, dose and type of anti-thymocyte globulin (ATG) administrated, as well as treatment intensity, did not alter the incidence of TB. Therefore, allo-HSCT recipients with unexplained fever, especially those who suffer from invasive fungal disease and ongoing immunosuppression with a relatively high dose of prednisone or tacrolimus, are at a high-risk of developing active TB. Closely Monitoring TB occurrence, making a timely diagnosis and administering the proper treatment may be beneficial to those high-risk patients.","language":"eng","number":"1","journal":"Scientific Reports","author":[{"propositions":[],"lastnames":["Yang"],"firstnames":["Apeng"],"suffixes":[]},{"propositions":[],"lastnames":["Shi"],"firstnames":["Jimin"],"suffixes":[]},{"propositions":[],"lastnames":["Luo"],"firstnames":["Yi"],"suffixes":[]},{"propositions":[],"lastnames":["Ye"],"firstnames":["Yishan"],"suffixes":[]},{"propositions":[],"lastnames":["Tan"],"firstnames":["Yamin"],"suffixes":[]},{"propositions":[],"lastnames":["Huang"],"firstnames":["He"],"suffixes":[]},{"propositions":[],"lastnames":["Zhao"],"firstnames":["Yanmin"],"suffixes":[]}],"month":"December","year":"2019","pmid":"31892702","pmcid":"PMC6938515","keywords":"Adolescent, Adult, Aged, Case-Control Studies, Child, Disease Susceptibility, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppression Therapy, Immunosuppressive Agents, Incidence, Invasive Fungal Infections, Male, Methotrexate, Middle Aged, Mycophenolic Acid, Prednisone, Risk, Transplant Recipients, Tuberculosis, Young Adult","pages":"20402","bibtex":"@article{yang_allo-hsct_2019,\n\ttitle = {Allo-{HSCT} recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis},\n\tvolume = {9},\n\tissn = {2045-2322},\n\tdoi = {10.1038/s41598-019-56013-w},\n\tabstract = {Patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of acquiring tuberculosis (TB) due to a status of immunosuppression. We conducted a nested case control study to investigate the incidence and risk factors for TB after allo-HSCT. Between 2012 and 2017, 730 consecutive allo-HSCT recipients were enrolled, and 14 patients (1.92\\%) were diagnosed with TB. Relatively, 54 allo-HSCT recipients were selected as control. Patients who suffered TB had a significantly higher 3-year non-relapse mortality rate than the control group (30.36\\% vs 5.39\\%, P {\\textless} 0.01). In multivariate analysis, invasive fungal disease (HR 4.87, 95\\% CI 1.39-17.09), treatment with a relatively high dose of prednisone (HR 10.34, 95\\% CI 1.12-95.47) and treatment with tacrolimus (HR 4.79, 95\\% CI 1.18-19.44) were identified independent risk factors for TB occurrence post allo-HSCT (P {\\textless} 0.05). Meanwhile, donor type, dose and type of anti-thymocyte globulin (ATG) administrated, as well as treatment intensity, did not alter the incidence of TB. Therefore, allo-HSCT recipients with unexplained fever, especially those who suffer from invasive fungal disease and ongoing immunosuppression with a relatively high dose of prednisone or tacrolimus, are at a high-risk of developing active TB. Closely Monitoring TB occurrence, making a timely diagnosis and administering the proper treatment may be beneficial to those high-risk patients.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Scientific Reports},\n\tauthor = {Yang, Apeng and Shi, Jimin and Luo, Yi and Ye, Yishan and Tan, Yamin and Huang, He and Zhao, Yanmin},\n\tmonth = dec,\n\tyear = {2019},\n\tpmid = {31892702},\n\tpmcid = {PMC6938515},\n\tkeywords = {Adolescent, Adult, Aged, Case-Control Studies, Child, Disease Susceptibility, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppression Therapy, Immunosuppressive Agents, Incidence, Invasive Fungal Infections, Male, Methotrexate, Middle Aged, Mycophenolic Acid, Prednisone, Risk, Transplant Recipients, Tuberculosis, Young Adult},\n\tpages = {20402},\n}\n\n","author_short":["Yang, A.","Shi, J.","Luo, Y.","Ye, Y.","Tan, Y.","Huang, H.","Zhao, Y."],"key":"yang_allo-hsct_2019","id":"yang_allo-hsct_2019","bibbaseid":"yang-shi-luo-ye-tan-huang-zhao-allohsctrecipientswithinvasivefungaldiseaseandongoingimmunosuppressionhaveahighriskfordevelopingtuberculosis-2019","role":"author","urls":{},"keyword":["Adolescent","Adult","Aged","Case-Control Studies","Child","Disease Susceptibility","Female","Hematopoietic Stem Cell Transplantation","Humans","Immunosuppression Therapy","Immunosuppressive Agents","Incidence","Invasive Fungal Infections","Male","Methotrexate","Middle Aged","Mycophenolic Acid","Prednisone","Risk","Transplant Recipients","Tuberculosis","Young Adult"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://api.zotero.org/users/5339168/collections/A4LBKFGR/items?key=RInNUiN7PJjU7zMJB627eWm4&format=bibtex&limit=100","dataSources":["D8eoSNMvkma5pR9eS"],"keywords":["adolescent","adult","aged","case-control studies","child","disease susceptibility","female","hematopoietic stem cell transplantation","humans","immunosuppression therapy","immunosuppressive agents","incidence","invasive fungal infections","male","methotrexate","middle aged","mycophenolic acid","prednisone","risk","transplant recipients","tuberculosis","young adult"],"search_terms":["allo","hsct","recipients","invasive","fungal","disease","ongoing","immunosuppression","high","risk","developing","tuberculosis","yang","shi","luo","ye","tan","huang","zhao"],"title":"Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis","year":2019}